Milestone Asset Management LLC Has $1.01 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Milestone Asset Management LLC lifted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 56.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,874 shares of the biotechnology company’s stock after purchasing an additional 1,037 shares during the period. Milestone Asset Management LLC’s holdings in United Therapeutics were worth $1,014,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wealth Enhancement Advisory Services LLC boosted its position in shares of United Therapeutics by 0.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after purchasing an additional 39 shares in the last quarter. MBM Wealth Consultants LLC boosted its position in shares of United Therapeutics by 1.9% during the fourth quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 41 shares in the last quarter. First Citizens Bank & Trust Co. boosted its position in shares of United Therapeutics by 1.8% during the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 48 shares in the last quarter. Signaturefd LLC boosted its position in shares of United Therapeutics by 8.8% during the third quarter. Signaturefd LLC now owns 633 shares of the biotechnology company’s stock worth $227,000 after purchasing an additional 51 shares in the last quarter. Finally, UMB Bank n.a. boosted its position in shares of United Therapeutics by 4.9% during the fourth quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company’s stock worth $388,000 after purchasing an additional 51 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other news, Director Christopher Causey sold 510 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the sale, the director now owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This represents a 12.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the transaction, the director now owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 149,048 shares of company stock valued at $56,142,199. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR opened at $372.75 on Thursday. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The firm has a market cap of $16.64 billion, a P/E ratio of 16.37, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57. The firm’s 50-day simple moving average is $365.77 and its 200 day simple moving average is $356.81.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the previous year, the firm posted $5.38 EPS. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, equities analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on UTHR shares. The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. LADENBURG THALM/SH SH boosted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, TD Cowen lifted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $378.36.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.